Presently, various FTO-targeting drugs, including entacapone, meclofenamic acid, betaine, exenatide, and curcumin, have been found to be promising in the treatment of NAFLD. The gene discussed is FTO; the disease is metabolic dysfunction-associated steatotic liver disease.